Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities
Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI, Starostin KM
Published in BMJ Open Gastroenterology, Vol. 7 (1), pp. e000341
Methodology
Prospective observational study of polyenylphosphatidylcholine added to standard care in patients with NAFLD and cardiometabolic comorbidities
Key Findings
Ultrasound-assessed steatosis and liver enzymes improved over 24 weeks of phosphatidylcholine treatment
Conclusions
Phosphatidylcholine may support improvement of hepatic steatosis alongside standard care
Limitations
Open-label, no control group, manufacturer sponsored, ultrasound endpoints
Supplements Studied
Ultrasound-assessed steatosis and liver enzymes improved over 24 weeks of phosphatidylcholine treatment
Outcomes Measured
Ultrasound-assessed steatosis and liver enzymes improved over 24 weeks of phosphatidylcholine treatment
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.